Literature DB >> 12444553

Expression of hpttg proto-oncogene in lymphoid neoplasias.

Carmen Sáez1, Teresa Pereda, Juan J Borrero, Agueda Espina, Francisco Romero, María Tortolero, José A Pintor-Toro, Dolores I Segura, Miguel A Japón.   

Abstract

Pituitary tumor-transforming gene (pttg) is a distinct proto-oncogene which is expressed in certain normal tissues with high proliferation rate and in a variety of tumors. PTTG is the vertebrate analog of yeast securins Pds1 and Cut2 with a key role in the regulation of sister chromatid separation during mitosis. Impairment of PTTG regulated functions is expected to lead to chromosomal instability and aneuploidy. Human pttg (hpttg) is abundantly expressed in Jurkat T lymphoblastic lymphoma cells but not in normal peripheral blood leukocytes. To obtain additional data on the potential role of hpttg in lymphomagenesis we selected 150 cases of lymphoid tumors for the assessment of hpttg expression in tumor tissues. Immunohistochemical studies on formalin-fixed, paraffin-embedded tissues revealed hPTTG in 38.8% of B-cell lymphomas, 70.2% of T-cell lymphomas, and 73.1% of Hodgkin's lymphomas. Among B-cell lymphomas, the most frequently immunostained tumors were plasma cell tumors, diffuse large cell lymphomas, and follicle center cell lymphomas. In Hodgkin's disease, immunoreactivity was mainly noted in Reed-Sternberg cells. In conclusion, the frequent overexpression of hpttg in many histological subtypes of lymphoma suggests the involvement of this proto-oncogene in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12444553     DOI: 10.1038/sj.onc.1205954

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

1.  Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors.

Authors:  Mar Mora-Santos; M Cristina Limón-Mortés; Servando Giráldez; Joaquín Herrero-Ruiz; Carmen Sáez; Miguel Á Japón; Maria Tortolero; Francisco Romero
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

Review 2.  The emerging role of pituitary tumor transforming gene in tumorigenesis.

Authors:  Jacob Tfelt-Hansen; Deepthi Kanuparthi; Naibedya Chattopadhyay
Journal:  Clin Med Res       Date:  2006-06

Review 3.  Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.

Authors:  Alisa B Lee-Sherick; Rachel M A Linger; Lia Gore; Amy K Keating; Douglas K Graham
Journal:  Br J Haematol       Date:  2010-08-31       Impact factor: 6.998

4.  Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase.

Authors:  Ana M Gil-Bernabé; Francisco Romero; M Cristina Limón-Mortés; María Tortolero
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

5.  PTTG promotes invasion in human breast cancer cell line by upregulating EMMPRIN via FAK/Akt/mTOR signaling.

Authors:  Hui Gao; Feng Zhong; Jing Xie; Jianjun Peng; Zhiwu Han
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

6.  Securin is a target of the UV response pathway in mammalian cells.

Authors:  Francisco Romero; Ana M Gil-Bernabé; Carmen Sáez; Miguel A Japón; José A Pintor-Toro; María Tortolero
Journal:  Mol Cell Biol       Date:  2004-04       Impact factor: 4.272

Review 7.  The pituitary tumor transforming gene in thyroid cancer.

Authors:  G D Lewy; N Sharma; R I Seed; V E Smith; K Boelaert; C J McCabe
Journal:  J Endocrinol Invest       Date:  2012-04-05       Impact factor: 4.256

8.  PTTG/securin activates expression of p53 and modulates its function.

Authors:  Tariq Hamid; Sham S Kakar
Journal:  Mol Cancer       Date:  2004-07-08       Impact factor: 27.401

9.  The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma.

Authors:  Maurizio Chiriva-Internati; Raffaele Ferrari; Madhavi Prabhakar; Yuefei Yu; Luigi Baggoni; Jorge Moreno; Nicoletta Gagliano; Nicola Portinaro; Marjorie R Jenkins; Eldo E Frezza; Fred Hardwicke; Nicholas D'Cunha; Wmartin Kast; Everardo Cobos
Journal:  J Transl Med       Date:  2008-04-02       Impact factor: 5.531

10.  PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma.

Authors:  Jacqueline E Noll; Kate Vandyke; Duncan R Hewett; Krzysztof M Mrozik; Rachel J Bala; Sharon A Williams; Chung H Kok; Andrew Cw Zannettino
Journal:  J Hematol Oncol       Date:  2015-10-06       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.